Skip to content

News

LEAP and CROI in Denver

Dr. Ho and his team attended and contributed to the LEAP workshop and CROI in Denver, highlighting their development in Drug-combination nanoparticle technology. This innovative technology simplifies and scales up the formulation of multiple antiretrovirals into a single injectable for long-acting HIV therpay.

During LEAP, Rodney updated attendees on the project’s progress over the last year. At CROI, their focus was on a poster presentation in the pediatric section, discussing a validated PBPK model for pediatric dosing.

Key topics at CROI included advancements in HIV vaccines, mAbs, long-acting injectables, and pediatric HIV treatment solutions.

For further details, contact tlcart@uw.edu.

 

 

 

 

 

 

 

 

 

 

 

 

TLC-ART featured on POZ.com

Prof. Ho’s Laboratory is featured on POZ.com, an influential print and online brand for people living with and affected by HIV/AIDS.

Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research introduces a groundbreaking long-acting injectable blend of tenofovir, lamivudine, and dolutegravir, proven effective for a month in primate studies. Leveraging cutting-edge nanoparticle technology, this formulation presents an accessible, possibly self-administered solution, marking a significant stride in enhancing HIV treatment and compliance, with particular promise for resource-limited settings.

https://www.poz.com/article/longerlasting-hiv-meds-horizon

 

HIV first-line TLD as one injectable lasting 1 month may be possible

TLC-ART can transform first-line 3 drugs TLD (tenofovir/lamivudine/tenofovir) as one long-acting injectable lasting 1 month in nonhuman primates

In a significant pharmaceutical breakthrough, researchers at our laboratory have successfully developed an innovative long-acting injectable version of the antiretroviral drug combination known as TLD, comprising tenofovir, lamivudine, and dolutegravir. This formulation, endorsed as the first-line treatment for HIV by the World Health Organization, employs advanced drug-combination nanoparticle technology. This technology significantly extends the duration of the drug’s presence in the bloodstream to up to one month with just a single injection. The groundbreaking results of this research, conducted on nonhuman primates for now, were recently published in the esteemed journal AIDS, garnering considerable attention and acclaim within the global AIDS research community.

The composition was made of generic and approved components, with public funding, and therefore costs should be limited, which can be of interest to low-mid income countries.

Additionally, leveraging the onboard tenofovir component, long-acting TLD holds the potential for coverage in people living with HIV and HBV.

NEWS:

AIDSmap

Spotlight

Research Article on AIDS

 

Prof Rodney Ho presented at IAS 2023 in Brisbane

Sept 12, 2023

Prof Ho presented TLC-ART work at IAS in Brisbane last July. TLC-ART has proposed the transformation of the short-acting HIV treatment, TLD (Tenofovir, Lamivudine, Dolutegravir), into a long-acting, single-injection formula that is stable in vivo and in nonhuman primates. This new formulation addresses “pill fatigue” and offers consistent treatment effects lasting over four weeks. This advancement paves the way for more efficient HIV treatments and a potential new standard in patient care.

IAS 2023 proceedings.

Contact: tlcart@uw.edu

Summary of 2022-2023 TLC-ART Conferences and Presentations to date

2023 LEAP CROI 2023 Workshop in Seattle – Rodney Ho and Simone Perazzolo as plenary talks.

LEAP Logo

February 20, Seattle

The Long-Acting Extended Release Antiretroviral Research Resource Program (LEAP) virtually convened clinicians, investigators, developers, community advocacy groups, not-for-profit institutions, and regulatory authorities. Attendees shared their diverse perspectives and discussed updates, challenges, and future directions in the development of LA formulations. The meeting served as a forum to collectively advance the long-acting field. The Workshop consisted of two Plenary Sessions and four Focus Groups. Below, you’ll find links to video recordings and text summaries of the Plenary and Focus Group presentations.

TLC-ART Lab Update on HIV Therapies at LEAP Conference

LEAP Logo

Seattle, WA (Feb 12, 2022)–Earlier this month, Dr. Rodney Ho presented updates on the TLC-ART program’s Unitaid funded Global Long-Acting Drug Development (GLAD) Project at the LEAP (Lon-Acting/Extended Release Antiretroviral Research Resource Program) annual meeting.

As part of this meeting, Dr. Ho lectured on the progress of the GLAD project in transforming the current best-of-class oral daily 3-drug pill (Tenofovir, Lamivudine, and Dolutegravir) into a long-acting injectable therapy that can improve patient adherence and provide a higher quality of life for People Living with HIV (PLHIV) globally.